For patients with non-large vessel occlusion, acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase administered 4.5 to 24 hours after stroke onset is associated with a higher likelihood of excellent functional outcome at 90 days, according to a study published online Feb. 5 in the Journal of the American Medical Association to coincide with the annual American Stroke Association International Stroke Conference, held from Feb. 4 to 6 in New Orleans.
This article was originally published on MedicalXpress.com
